← All stories
Markets
HUTCHMED Secures NMPA Conditional Approval for ATLED® (Fanregratinib) to Treat FGFR2-Altered Intrahepatic Cholangiocarcinoma in China
HUTCHMED (China) Limited (Nasdaq/AIM: HCM; HKEX: 13) announced that China's National Medical Products Administration (NMPA) has granted conditional approval for ATLED® (fanregratinib, HMPL-453) to treat adult patients with advanced, metasta…
Covered by 1 outlet
All coverage · 1 article